Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edecesertib in Cutaneous Lupus Erythematosus
NCT04809623Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) comparing Edecesertib with Placebo (2 arms). Primary endpoints: Percentage of Participants Who Experienced Treatment-emergent Adverse Events and Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities. Started Sep 2021; status: terminated.
02
Drugs
edecesertib
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT04809623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809623.